$12.67
3.28% yesterday
NYSE, Jun 13, 10:00 pm CET
ISIN
CA98985W1023
Symbol
ZYME
Sector
Industry

Zymeworks Inc. Stock price

$12.67
+1.06 9.13% 1M
+0.09 0.72% 6M
-1.97 13.46% YTD
+3.56 39.08% 1Y
-22.95 64.43% 5Y
-0.33 2.54% 10Y
-0.33 2.54% 20Y
NYSE, Closing price Fri, Jun 13 2025
-0.43 3.28%
ISIN
CA98985W1023
Symbol
ZYME
Sector
Industry

Key metrics

Market capitalization $890.11m
Enterprise Value $625.14m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.70
P/S ratio (TTM) P/S ratio 9.54
P/B ratio (TTM) P/B ratio 2.73
Revenue growth (TTM) Revenue growth 84.84%
Revenue (TTM) Revenue $93.27m
EBIT (operating result TTM) EBIT $-125.00m
Free Cash Flow (TTM) Free Cash Flow $-78.17m
Cash position $265.00m
EPS (TTM) EPS $-1.53
P/E forward negative
P/S forward 8.78
EV/Sales forward 6.17
Short interest 13.39%
Show more

Is Zymeworks Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Zymeworks Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Zymeworks Inc. forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Zymeworks Inc. forecast:

Buy
80%
Hold
20%

Financial data from Zymeworks Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
93 93
85% 85%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 63 63
9% 9%
68%
- Research and Development Expense - -
-
-
-121 -121
13% 13%
-130%
- Depreciation and Amortization 4.11 4.11
57% 57%
4%
EBIT (Operating Income) EBIT -125 -125
16% 16%
-134%
Net Profit -115 -115
9% 9%
-123%

In millions USD.

Don't miss a Thing! We will send you all news about Zymeworks Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Zymeworks Inc. Stock News

Neutral
Seeking Alpha
2 days ago
Zymeworks Inc.'s lead asset zanidatamab won FDA approval for HER2-positive biliary tract cancer, validating its platform but addressing a small market. The main investment thesis hinges on upcoming Phase 3 data for zanidatamab in first-line HER2-positive gastroesophageal adenocarcinoma, a much larger opportunity. Partnerships with Jazz and BeiGene provide non-dilutive funding and milestone paym...
Neutral
GlobeNewsWire
15 days ago
VANCOUVER, British Columbia, May 30, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that the National Medical Products Administration (NMPA)...
Neutral
GlobeNewsWire
23 days ago
VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced multiple presentations related to its oncology programs ...
More Zymeworks Inc. News

Company Profile

Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.

Head office Canada
CEO Ken Galbraith
Employees 283
Founded 2003
Website www.zymeworks.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today